BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38083755)

  • 1. Simulating the Evolution of Signaling Signatures During CART-Cell and Tumor Cell Interactions.
    Shah V; Womack J; Zamora AE; Terhune SS; Dash RK
    Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-5. PubMed ID: 38083755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulating the Evolution of Signaling Signatures during CART-Cell - Tumor Cell Interactions.
    Shah V; Womack J; Zamora AE; Terhune SS; Dash RK
    ArXiv; 2023 Feb; ():. PubMed ID: 36798455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
    Haas AR; Tanyi JL; O'Hara MH; Gladney WL; Lacey SF; Torigian DA; Soulen MC; Tian L; McGarvey M; Nelson AM; Farabaugh CS; Moon E; Levine BL; Melenhorst JJ; Plesa G; June CH; Albelda SM; Beatty GL
    Mol Ther; 2019 Nov; 27(11):1919-1929. PubMed ID: 31420241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR Takes the Front Seat in CART-Cell Development.
    Manriquez-Roman C; Siegler EL; Kenderian SS
    BioDrugs; 2021 Mar; 35(2):113-124. PubMed ID: 33638865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy.
    Stock S; Schmitt M; Sellner L
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
    Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
    Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.
    Lee YH; Kim CH
    Arch Pharm Res; 2019 Jul; 42(7):607-616. PubMed ID: 30830661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.
    Ramakrishna S; Highfill SL; Walsh Z; Nguyen SM; Lei H; Shern JF; Qin H; Kraft IL; Stetler-Stevenson M; Yuan CM; Hwang JD; Feng Y; Zhu Z; Dimitrov D; Shah NN; Fry TJ
    Clin Cancer Res; 2019 Sep; 25(17):5329-5341. PubMed ID: 31110075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cryopreservation on chimeric antigen receptor T cell functions.
    Xu H; Cao W; Huang L; Xiao M; Cao Y; Zhao L; Wang N; Zhou J
    Cryobiology; 2018 Aug; 83():40-47. PubMed ID: 29908946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.
    Holland EM; Yates B; Steinberg SM; Yuan CM; Wang HW; Annesley C; Shalabi H; Stroncek D; Fry TJ; Krueger J; Jacoby E; Hsieh E; Bhojwani D; Gardner RA; Maude SL; Shah NN
    Transplant Cell Ther; 2023 Sep; 29(9):574.e1-574.e10. PubMed ID: 37394115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics.
    Panch SR; Srivastava SK; Elavia N; McManus A; Liu S; Jin P; Highfill SL; Li X; Dagur P; Kochenderfer JN; Fry TJ; Mackall CL; Lee D; Shah NN; Stroncek DF
    Mol Ther; 2019 Jul; 27(7):1275-1285. PubMed ID: 31178392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.
    Lee YG; Guruprasad P; Ghilardi G; Pajarillo R; Sauter CT; Patel R; Ballard HJ; Hong SJ; Chun I; Yang N; Amelsberg KV; Cummins KD; Svoboda J; Gill S; Chong EA; North K; Church SE; Fraietta JA; Chang WJ; Lacey SF; Lu XM; Zhang Y; Whig K; Schultz DC; Cherry S; Gerson J; Schuster SJ; Porazzi P; Ruella M
    Cancer Discov; 2022 Oct; 12(10):2372-2391. PubMed ID: 35904479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Driving cars to the clinic for solid tumors.
    Castellarin M; Watanabe K; June CH; Kloss CC; Posey AD
    Gene Ther; 2018 Jun; 25(3):165-175. PubMed ID: 29880908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers.
    Guo Y; Feng K; Liu Y; Wu Z; Dai H; Yang Q; Wang Y; Jia H; Han W
    Clin Cancer Res; 2018 Mar; 24(6):1277-1286. PubMed ID: 29138340
    [No Abstract]   [Full Text] [Related]  

  • 17. The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy.
    Schubert ML; Rohrbach R; Schmitt M; Stein-Thoeringer CK
    Front Immunol; 2021; 12():670286. PubMed ID: 34135898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.
    Feng K; Liu Y; Guo Y; Qiu J; Wu Z; Dai H; Yang Q; Wang Y; Han W
    Protein Cell; 2018 Oct; 9(10):838-847. PubMed ID: 28710747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
    Cummins KD; Gill S
    Leuk Lymphoma; 2018 Jul; 59(7):1539-1553. PubMed ID: 28901790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.
    Ko AH; Jordan AC; Tooker E; Lacey SF; Chang RB; Li Y; Venook AP; Tempero M; Damon L; Fong L; O'Hara MH; Levine BL; Melenhorst JJ; Plesa G; June CH; Beatty GL
    Mol Ther; 2020 Nov; 28(11):2367-2378. PubMed ID: 32730744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.